Tus Pharmaceutical Group Co Ltd

SHE:000590 China Drug Manufacturers - Specialty & Generic
Market Cap
$394.92 Million
CN¥2.90 Billion CNY
Market Cap Rank
#12556 Global
#3126 in China
Share Price
CN¥12.10
Change (1 day)
-0.17%
52-Week Range
CN¥7.90 - CN¥14.30
All Time High
CN¥26.17
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

Guhan Pharmaceutical Group Co., Ltd., together with its subsidiaries, manufactures and sells traditional Chinese medicines, chemical drugs, and health food in China. It operates through the Production and Sales of Traditional Chinese Medicine; Production and Sales of Western Medicine; and Other Operations segments. The company offers prescription and over-the-counter drugs, such as tonic and heal… Read more

Tus Pharmaceutical Group Co Ltd (000590) - Net Assets

Latest net assets as of September 2025: CN¥585.85 Million CNY

Based on the latest financial reports, Tus Pharmaceutical Group Co Ltd (000590) has net assets worth CN¥585.85 Million CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥945.59 Million) and total liabilities (CN¥359.74 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥585.85 Million
% of Total Assets 61.96%
Annual Growth Rate 7.95%
5-Year Change -6.77%
10-Year Change 192.15%
Growth Volatility 36.22

Tus Pharmaceutical Group Co Ltd - Net Assets Trend (1995–2024)

This chart illustrates how Tus Pharmaceutical Group Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Tus Pharmaceutical Group Co Ltd (1995–2024)

The table below shows the annual net assets of Tus Pharmaceutical Group Co Ltd from 1995 to 2024.

Year Net Assets Change
2024-12-31 CN¥601.23 Million -17.44%
2023-12-31 CN¥728.20 Million +3.66%
2022-12-31 CN¥702.49 Million +2.96%
2021-12-31 CN¥682.32 Million +5.81%
2020-12-31 CN¥644.88 Million +3.65%
2019-12-31 CN¥622.16 Million +7.32%
2018-12-31 CN¥579.72 Million -0.62%
2017-12-31 CN¥583.33 Million +121.00%
2016-12-31 CN¥263.96 Million +28.26%
2015-12-31 CN¥205.79 Million +11.78%
2014-12-31 CN¥184.11 Million -31.69%
2013-12-31 CN¥269.51 Million -43.69%
2012-12-31 CN¥478.58 Million +36.41%
2011-12-31 CN¥350.83 Million +25.80%
2010-12-31 CN¥278.88 Million +20.61%
2009-12-31 CN¥231.22 Million -28.36%
2008-12-31 CN¥322.78 Million +5.07%
2007-12-31 CN¥307.22 Million +13.26%
2006-12-31 CN¥271.26 Million +1.01%
2005-12-31 CN¥268.54 Million +0.36%
2004-12-31 CN¥267.57 Million +3.24%
2003-12-31 CN¥259.16 Million -7.74%
2002-12-31 CN¥280.91 Million +0.81%
2001-12-31 CN¥278.65 Million -26.67%
2000-12-31 CN¥380.02 Million +9.26%
1999-12-31 CN¥347.80 Million +29.40%
1998-12-31 CN¥268.78 Million +11.57%
1997-12-31 CN¥240.92 Million +69.77%
1996-12-31 CN¥141.91 Million +117.26%
1995-12-31 CN¥65.32 Million --

Equity Component Analysis

This analysis shows how different components contribute to Tus Pharmaceutical Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 73498.4% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock CN¥239.47 Million 40.03%
Other Components CN¥519.96 Million 86.91%
Total Equity CN¥598.25 Million 100.00%

Tus Pharmaceutical Group Co Ltd Competitors by Market Cap

The table below lists competitors of Tus Pharmaceutical Group Co Ltd ranked by their market capitalization.

Company Market Cap
Shanghai Kindly Entrp Dvlp Grp
SHG:603987
 		$317.14 Million
Luoyang Northglass Technology Co Ltd
SHE:002613
 		$317.38 Million
Ningbo Daye Garden Machinery Co Ltd
SHE:300879
 		$317.38 Million
Eco-Shop Marketing Berhad
KLSE:5337
 		$317.39 Million
Novavest Real Estate Ag
SW:NREN
 		$317.04 Million
Camelot Electronics Technology Co. Ltd. A
SHE:301282
 		$317.01 Million
Berli Jucker PCL
BK:BJC
 		$316.94 Million
Wuhan Sanzhen Industry Holding Co Ltd
SHG:600168
 		$316.91 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Tus Pharmaceutical Group Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 723,717,642 to 598,246,119, a change of -125,471,523 (-17.3%).
  • Net loss of 125,471,522 reduced equity.
  • Dividend payments of 3,465,326 reduced retained earnings.
  • Other comprehensive income decreased equity by 142,595,381.
  • Other factors increased equity by 146,060,706.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥-125.47 Million -20.97%
Dividends Paid CN¥3.47 Million -0.58%
Other Comprehensive Income CN¥-142.60 Million -23.84%
Other Changes CN¥146.06 Million +24.41%
Total Change CN¥- -17.34%

Book Value vs Market Value Analysis

This analysis compares Tus Pharmaceutical Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 4.84x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 41.35x to 4.84x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1995-12-31 CN¥0.29 CN¥12.10 x
1996-12-31 CN¥0.64 CN¥12.10 x
1997-12-31 CN¥1.08 CN¥12.10 x
1998-12-31 CN¥1.20 CN¥12.10 x
1999-12-31 CN¥1.56 CN¥12.10 x
2000-12-31 CN¥1.68 CN¥12.10 x
2001-12-31 CN¥1.25 CN¥12.10 x
2002-12-31 CN¥1.27 CN¥12.10 x
2003-12-31 CN¥1.16 CN¥12.10 x
2004-12-31 CN¥1.20 CN¥12.10 x
2005-12-31 CN¥1.21 CN¥12.10 x
2006-12-31 CN¥1.21 CN¥12.10 x
2007-12-31 CN¥1.36 CN¥12.10 x
2008-12-31 CN¥1.45 CN¥12.10 x
2009-12-31 CN¥1.04 CN¥12.10 x
2010-12-31 CN¥1.30 CN¥12.10 x
2011-12-31 CN¥1.62 CN¥12.10 x
2012-12-31 CN¥2.14 CN¥12.10 x
2013-12-31 CN¥1.21 CN¥12.10 x
2014-12-31 CN¥0.82 CN¥12.10 x
2015-12-31 CN¥0.92 CN¥12.10 x
2016-12-31 CN¥1.17 CN¥12.10 x
2017-12-31 CN¥2.51 CN¥12.10 x
2018-12-31 CN¥2.42 CN¥12.10 x
2019-12-31 CN¥2.60 CN¥12.10 x
2020-12-31 CN¥2.69 CN¥12.10 x
2021-12-31 CN¥2.84 CN¥12.10 x
2022-12-31 CN¥2.92 CN¥12.10 x
2023-12-31 CN¥3.02 CN¥12.10 x
2024-12-31 CN¥2.50 CN¥12.10 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Tus Pharmaceutical Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -20.97%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -36.56%
  • • Asset Turnover: 0.34x
  • • Equity Multiplier: 1.69x
  • Recent ROE (-20.97%) is below the historical average (-0.00%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1995 20.59% 14.33% 0.67x 2.16x CN¥6.92 Million
1996 11.01% 22.63% 0.37x 1.32x CN¥1.44 Million
1997 10.02% 18.02% 0.36x 1.55x CN¥41.23K
1998 10.37% 14.05% 0.49x 1.50x CN¥986.96K
1999 3.59% 5.67% 0.37x 1.72x CN¥-22.26 Million
2000 8.08% 10.70% 0.45x 1.70x CN¥-7.20 Million
2001 -21.32% -24.29% 0.35x 2.48x CN¥-87.66 Million
2002 1.44% 1.38% 0.41x 2.55x CN¥-24.29 Million
2003 -10.15% -11.02% 0.35x 2.65x CN¥-52.08 Million
2004 2.03% 2.03% 0.39x 2.53x CN¥-21.32 Million
2005 1.59% 1.58% 0.41x 2.47x CN¥-22.63 Million
2006 1.07% 1.01% 0.53x 2.01x CN¥-24.24 Million
2007 6.68% 9.87% 0.38x 1.79x CN¥-10.20 Million
2008 6.31% 8.61% 0.41x 1.77x CN¥-11.90 Million
2009 -38.13% -32.17% 0.53x 2.23x CN¥-111.29 Million
2010 16.30% 15.13% 0.55x 1.97x CN¥18.22 Million
2011 19.97% 21.00% 0.57x 1.67x CN¥36.01 Million
2012 28.75% 37.86% 0.52x 1.47x CN¥89.75 Million
2013 -61.02% -64.24% 0.46x 2.05x CN¥-191.40 Million
2014 -46.59% -42.23% 0.35x 3.19x CN¥-104.18 Million
2015 10.87% 7.59% 0.50x 2.85x CN¥1.79 Million
2016 21.14% 17.38% 0.50x 2.42x CN¥29.08 Million
2017 3.29% 5.58% 0.39x 1.50x CN¥-39.16 Million
2018 -6.59% -20.55% 0.23x 1.41x CN¥-96.15 Million
2019 6.82% 13.47% 0.37x 1.36x CN¥-19.77 Million
2020 3.52% 8.26% 0.31x 1.38x CN¥-41.77 Million
2021 5.21% 11.78% 0.31x 1.42x CN¥-32.59 Million
2022 2.59% 5.17% 0.30x 1.67x CN¥-51.74 Million
2023 3.49% 6.24% 0.35x 1.59x CN¥-47.12 Million
2024 -20.97% -36.56% 0.34x 1.69x CN¥-185.30 Million

Industry Comparison

This section compares Tus Pharmaceutical Group Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $2,330,043,965
  • Average return on equity (ROE) among peers: 6.53%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Tus Pharmaceutical Group Co Ltd (000590) CN¥585.85 Million 20.59% 0.61x $317.08 Million
Shenzhen Neptunus Bioengineering Co Ltd (000078) $6.47 Billion 9.88% 3.77x $616.08 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $1.18 Billion 2.74% 0.95x $320.56 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $10.33 Billion 15.07% 0.27x $3.03 Billion
Wedge Industrial Co Ltd (000534) $298.72 Million 1.96% 0.38x $1.77 Billion
Yunnan Baiyao Group Co Ltd (000538) $35.11 Million 18.13% 0.80x $5.62 Billion
Hainan Haiyao Co Ltd (000566) $353.98 Million -9.58% 0.80x $702.18 Million
Northeast Pharmaceutical Group Co Ltd (000597) $927.49 Million 2.65% 1.38x $425.60 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $1.11 Billion 7.32% 0.29x $2.05 Billion
Renhe Pharmacy Co Ltd (000650) $261.49 Million 10.60% 0.82x $777.45 Million